Transitioning GHD Patients from Pediatric to Adult Care — Challenges and Best Practices

This episode addresses transition of care in GHD — widely recognized as one of the most clinically vulnerable periods for patients, with high rates of dropout and delayed or lost treatment.

Dr. Alter identifies the fundamental challenge from the pediatric side: finding adult endocrinologists with pituitary disease expertise and availability. Wait times for established pituitary specialists can stretch up to a year. His institution works proactively to cultivate relationships with adult endocrinologists across the Philadelphia region to ensure continuity.

Dr. Agrawal describes NYU’s collaborative approach: pediatric colleagues begin flagging patients for potential adult GH therapy as early as age 11–12, aiming for a smooth transition around ages 14–15. This advance communication allows time for retesting decisions, insurance prior authorizations, and documentation to be completed before treatment gaps occur.

A major concern raised by both Dr. Agrawal and Dr. Garcia is patient dropout. Patients who have formed trusted relationships with their pediatric endocrinologists are often reluctant to transfer care, and many are simply lost to follow-up. Those with structural pituitary disease face the most serious consequences if GH therapy lapses — including progressive weight gain, bone loss, and lean mass depletion.

The panel stresses the importance of beginning conversations about the adult role of GH early — before the patient stops growing. Patients often assume GHD ends with growth, so educating them that GH continues to support bone accrual (which peaks in the mid-20s) and body composition into adulthood is essential to sustaining motivation.

The panel recommends structured tools to facilitate transitions: patient handouts summarizing GH history and test results, and ideally a joint pediatric-adult transition clinic — a model not yet widely implemented but recognized as the gold standard.

Navigating Insurance, Documentation, and Access Barriers in Adult GHD Management

,” the panel examines the practical obstacles clinicians face in getting adult GHD therapy authorized and sustained, and strategies for overcoming them.

Videos

How to keep growth hormone deficiency patients on track when moving to adult care—cutting waitlists, dropouts, and insurance delays.

Dosing and Managing Long-Acting GH Therapy in Adults — Clinical Factors, Titration, and Side Effects

This episode examines adult-specific dosing and management strategies for long-acting GH analogs, with attention to clinical factors that guide formulation selection, titration targets, and the management of side effects more common in adults than children.

Dr. Garcia and Dr. Agrawal outline their approach to selecting between daily and weekly GH in adult patients. In an ideal world, patient preference and adherence would be the primary drivers. Dr. Garcia describes a patient in law enforcement who could not carry needles into a correctional facility — making weekly GH not just preferred but functionally necessary. Dr. Agrawal states she would switch all appropriate adult patients to weekly formulations if insurance access allowed, given the convenience and adherence benefits.

Adult dosing for long-acting analogs is non-weight-based and age-stratified. For somapacitan, the standard adult starting dose is 1.5 mg/week, though clinicians typically initiate lower (e.g., 1 mg/week) and titrate up. Elderly patients (>60–70 years) and those with poorly controlled type 2 diabetes start even lower. Women on oral estrogen (birth control pills) — due to hepatic GH resistance — may require a higher starting dose (2 mg/week). For lonapegsomatropin, dosing tiers of 0.7, 1.4, and 2.1 mg/week are adjusted based on patient age, sex hormone use, and comorbidities.

IGF-1 monitoring in adults should occur at mid-week (day 3–4 for somapacitan; day 4–5 for lonapegsomatropin) to capture the pharmacokinetic midpoint. Target IGF-1 is 0 to +2 standard deviation score above the mean. However, adults frequently experience side effects — particularly edema, arthralgias, and carpal tunnel symptoms — that limit dose escalation before the IGF-1 target is reached.

Dr. Garcia emphasizes the need to assess baseline joint symptoms before initiating GH, since arthralgia is the most common adult side effect and often indistinguishable from pre-existing musculoskeletal complaints.

,” the panel addresses one of the most clinically challenging aspects of GHD management: navigating the handoff from pediatric to adult endocrinology and preventing loss to follow-up.

Clinicians explain practical weekly growth hormone dosing—weight-based, pen-device rounding, and IGF‑1 checks—plus how puberty, fatigue, and growth velocity guide stopping therapy.

Dosing Long-Acting GH Analogs — Practical Considerations for Pediatric Patients

This episode takes a granular look at the practical realities of prescribing and dosing long-acting GH analogs in pediatric patients, from navigating pen device constraints to IGF-1 monitoring and end-of-treatment decision-making.

Dr. Alter opens with a discussion of lonapegsomatropin dosing at 0.24 mg/kg/week. In his practice, dosing tables pre-programmed in Epic (the EHR system) automatically calculate the appropriate fixed dose by weight range, eliminating manual calculation errors. He encourages practices to set up similar tools.

For somapacitan and somatrogon — which use pen delivery devices — dosing becomes more complex. Dr. Alter explains that fixed pen cartridge sizes (e.g., 15 mg for somapacitan) may not align neatly with weight-based calculations. He recommends rounding down to the nearest practical dose (e.g., from 5.3 mg to 5.0 mg) to avoid asking families to perform multi-step arithmetic. As children grow beyond 50 kg, they may occasionally require two injections on the same weekly dosing day.

Dr. Yang highlights a key practical nuance: the three analogs have completely different molecular weights, pharmacokinetics, and delivery systems — meaning dosing in mg/kg/week varies substantially. Lonapegsomatropin: 0.24 mg/kg/week; somapacitan: 0.16 mg/kg/week; somatrogon: 0.66 mg/kg/week. Though the numbers appear different, they reflect different molecular configurations rather than different pharmacologic potency.

The episode then shifts to the question of when to stop GH therapy in pediatric patients approaching growth completion. Dr. Alter explains that the decision is individualized. Today, Dr. Alter continues GH as long as the patient is clearly growing — even with advanced bone age — unless compliance fatigue, family preferences, or height goals have been achieved. A two-heights-the-same rule (no growth over 6 months) signals the true end of linear growth.

,” the panel examines adult-specific dosing strategies, titration frameworks, and the side effect profile that distinguishes adult GH therapy from the pediatric experience.

Clinicians share practical long‑acting growth hormone dosing tips, from pen‑based rounding to IGF‑1 adjustments, plus when to continue or stop therapy in puberty.

Real-World Registry Data for Long-Acting GH Analogs — SkybriGHt, SkyPASS, ANSWER, and Beyond

This episode explores how real-world registries are filling the evidence gaps left by clinical trials in GHD management, with a focus on treatment patterns, safety surveillance, and long-term outcomes for both pediatric and adult patients.

Dr. Yang introduces the SkyBright and SkyPass registries, established specifically to track real-world use of lonapegsomatropin in pediatric GHD patients. First-year data (100 patients) presented at the Pediatric Endocrine Society showed that real-world average IGF-1 was lower (+1.3 SDS) than the enliGHten trial average (+1.8 SDS), likely because clinicians in practice are more conservative with dosing than in trials. Some providers also initiated at doses below the labeled 0.24 mg/kg/week.

Dr. Garcia highlights the ANSWER registry, designed to track real-world adult GHD outcomes. He notes that cancer survivor data — a particularly vulnerable and high-need subgroup — will only emerge meaningfully from large real-world registries over time. This population’s long-term GH safety profile cannot be adequately addressed in short-duration clinical trials.

The panel draws lessons from legacy registries — KIGS and NCGS — which tracked daily GH outcomes over decades, ultimately confirming the long-term safety and efficacy of daily GH. The panel anticipates that similar maturation will occur for long-acting analogs, and that long-term registry data will be the deciding factor for clinicians who remain hesitant.

Dr. Yang notes important methodological improvements: in 2023, the FDA issued guidance to standardize registry design and data collection, improving the comparability and regulatory relevance of registry outputs. Non-pharma-sponsored registries — such as GloBE-Reg and the German INSIGHTS-GHT registry — are also capturing comparative daily vs. weekly outcomes without commercial bias.

,” the panel dives into the practical nuances of dosing all three long-acting analogs in children, including pen device limitations, rounding strategies, and IGF-1-guided titration.

Extension Data for Other Long-Acting GH Analogs

This episode reviews the trial and extension data for the two remaining FDA-approved long-acting GH analogs — somapacitan (REAL3 pediatric; REAL1 adult) and somatrogon (pediatric) — and addresses the question of whether higher IGF-1 levels seen with long-acting formulations translate to clinical difference in efficacy.

Dr. Yang presents the REAL3 trial data for somapacitan in pediatric GHD. The trial used a peak-trough-average IGF-1 methodology, yielding IGF-1 values within the −2 to +2 range. Dr. Yang poses a provocative question: if long-acting analogs produce higher average IGF-1 levels than daily GH yet achieve similar height velocities, does IGF-1 level actually drive growth outcomes, or is it merely a surrogate?

Dr. Alter confirms that across the somapacitan extension data, height velocity responses were excellent — over 7 cm/year on average. Both continued-weekly and switched-to-weekly groups performed comparably, offering reassurance that transitioning mid-treatment is safe and effective.

Dr. Agrawal then reviews the adult REAL1 trial for somapacitan (~300 patients, 34-week primary phase with 52-week extension, three arms: weekly somapacitan, daily GH, weekly placebo). Weekly somapacitan demonstrated non-inferiority to daily GH and superiority over placebo in reducing visceral adiposity and increasing lean body mass. No safety signals were identified.

The episode closes with a review of somatrogon, approved for pediatric GHD in 2023. Extension trial data show IGF-1 SDS of approximately +1.2 to +1.4, with strong efficacy and safety profiles. However, the adult somatrogon trial did not meet its primary endpoint of fat mass change, and the data remain unpublished in peer-reviewed journals. Panelists note this likely reflects study design issues rather than a true lack of biologic effect.

Real-World Registry Data for Long-Acting GH Analogs — SkyBright, SkyPass, ANSWER, and Beyond

,” the panel examines what real-world registries reveal about treatment patterns, safety, and outcomes in GHD, and how they compare to clinical trial findings.

Weekly lonapegsomatropin shows safe, effective growth hormone therapy, but IGF-1 may run high—learn dosing insights and adult trial outcomes.

Weekly growth hormone cuts injections—learn how it’s designed, who benefits, and key safety unknowns for cancer survivors and diabetes.

Extension Data for Long-Acting GH Analog Lonapegsomatropin in Pediatric and Adult GHD

Clinicians tailor adult growth hormone therapy, titrating doses via IGF-1, age, estrogen effects, side effects, and prioritizing quality-of-life gains over numbers.

Long-Acting Growth Hormone Analogs —Benefits and Safety Considerations

Adult growth hormone therapy starts low and titrates by IGF-1, age, and comorbidities, prioritizing quality-of-life gains and managing estrogen-related resistance.

Initiating and Managing Growth Hormone Therapy in Adults

Experts reveal gaps in growth hormone deficiency care: better diagnostics, biomarkers, and training to improve pediatric and adult treatment access.

Initiating Growth Hormone Therapy in Pediatric Patients

Learn key signs of pediatric growth hormone deficiency, when they appear, and why timely diagnosis boosts growth, strength, and long-term health.

Unmet Needs in Growth Hormone Deficiency Management 

How pediatric endocrinologists evaluate poor growth: key labs, IGF-1/IGFBP-3, stimulation testing, and ruling out celiac, Crohn’s, thyroid disease.

Growth Hormone Deficiency in Adults — Presentation, Quality of Life, and Diagnostic Challenges

Examining the 2026 ACC/AHA Dyslipidemia Guidelines for ASCVD

ASCVD Risk Assessment and LDL-C Management

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Articles

FDA updates, phase 3 CRISPR data in HAE, and emerging food allergy prevention strategies defined allergy and immunology news in April 2026.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

5 Allergy Headlines You Missed in April 2026

Learn how clinicians evaluate poor growth in kids—key labs, IGF‑1 clues, stimulation tests, and ruling out celiac, Crohn’s, thyroid issues.

Latest News

Transitioning GHD Patients from Pediatric to Adult Care — Challenges and Best Practices

Dosing and Managing Long-Acting GH Therapy in Adults — Clinical Factors, Titration, and Side Effects

Dosing Long-Acting GH Analogs — Practical Considerations for Pediatric Patients

Real-World Registry Data for Long-Acting GH Analogs — SkybriGHt, SkyPASS, ANSWER, and Beyond

Extension Data for Other Long-Acting GH Analogs